Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 11/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.56 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26538989 | 0.91 | CYP1A2 (0.56) | CYP1A2SCN5AMETSCN1ASCN2A | |
| SCHEMBL20203820 | 0.91 | CYP1A2 (0.69) | CYP1A2SCN5AALOX5APFEN1SCN1A | |
| SCHEMBL26538938 | 0.86 | CYP1A2 (0.54) | CYP1A2SCN5A | |
| SCHEMBL26539042 | 0.86 | CYP1A2 (0.58) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL26539040 | 0.85 | CYP1A2 (0.55) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL26539119 | 0.84 | CYP1A2 (0.59) | CYP1A2SCN5AMETSCN1ASCN2A | |
| SCHEMBL26539054 | 0.82 | CYP1A2 (0.52) | CYP1A2SCN5AMETSCN1ASCN2A | |
| SCHEMBL26539501 | 0.81 | CYP1A2 (0.48) | CYP1A2SCN5APRKD3MAP4K4CSNK1D | |
| SCHEMBL26539261 | 0.81 | CYP1A2 (0.53) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL20203737 | 0.81 | CYP1A2 (0.69) | CYP1A2SCN5ASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885ALOX5AP 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.